Aarti Drugs News

Aarti Drugs Invests ₹10 Crore in Subsidiary

Aarti Drugs Limited approves ₹10 crore investment in wholly owned subsidiary Pinnacle Life Science through rights issue subscription for expansion and capex funding.

Aarti Drugs Forms New Chilean Subsidiary

Aarti Drugs Limited announces incorporation of step-down subsidiary Tripharma Chile SpA through its existing subsidiary Pinnacle Chile SpA for pharmaceutical marketing operations in Chile.

Aarti Drugs Declares ₹2 Interim Dividend Per Share

Aarti Drugs announces interim dividend of ₹2 per share for shareholders, demonstrating the company's commitment to returning value to investors through regular dividend distributions.

Aarti Drugs Q3 Net Profit Rises 9.7% to ₹406M

Aarti Drugs reports consolidated net profit of ₹406 million in Q3, up from ₹370 million year-on-year. Revenue increased to ₹6 billion from ₹5.57 billion in the same period last year.

Aarti Drugs Gets CRISIL Rating Reaffirmation

CRISIL Limited reaffirmed Aarti Drugs' credit ratings with AA-/Stable for long-term and A1+ for short-term facilities totaling Rs. 1,768 crores across multiple banking partners.